Clinical Evidence
The Biochemical Baseline: Proving the Receptor Mechanism
Published in Biochemical and Biophysical Research Communications (BBRC), this foundational study establishes the biophysical reality of the rs5522 mineralocorticoid receptor variant. By mapping the receptor’s intense binding affinity, this paper provides the definitive laboratory proof backing the "cortisol steal"—demonstrating exactly how an overactive MR receptor drives cellular-level capture of corticosteroids that directly ignites tissue inflammation and systemic dysregulation.
Spironolactone for ME/CFS in a Patient Homozygous for rs5522 (I180V): A Case Report
This case report documents the successful, long-term reversal of 28-year treatment-resistant ME/CFS, offering a detailed, clinical roadmap for overcoming this condition. It presents a comprehensive, evidence-based argument that chronic inflammation is the core mechanism driving nearly all modern chronic illnesses.
Spironolactone Off-Label Therapeutic Benefit in ME/CFS
First published in the Internal Medicine Journal (2021), this open-label clinical trial led by Dr. Jorge Do Campo evaluated the off-label use of spironolactone for ME/CFS. The trial demonstrated rapid improvements in brain fog, cognitive clarity, and physical tolerance by targeting underlying neuro-inflammation.
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome
This landmark study provides direct neuroimaging proof of Dr. Jorge Do Campo’s protocol in action, showing visible microstructural repair in the brain's white-matter tracts following treatment. By moving past standard blood panels and utilizing advanced diffusion MRI, it provides objective, peer-reviewed validation that a low-dose spironolactone regimen in ME/CFS physically reverses central nervous system neuroinflammation.
Spironolactone reduces COVID-19 risk: real-time meta-analysis of 12 studies
A real-time meta-analysis of 12 global studies, covering over 20,000 patients, indicates that spironolactone significantly reduces the risk of severe COVID-19 progression and mortality. By blocking the hyper-inflammatory RAAS cascade and endothelial fluid leaks, this data supports the use of mineralocorticoid receptor (MR) antagonists to mitigate tissue-level vascular stress associated with both acute infection and long COVID. For more details, visit c19early.org.
Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series
A 2014 study in the Scandinavian Journal of Pain found that adding spironolactone to treatment regimens significantly improved widespread pain, stiffness, fatigue, anxiety, and depression in women with treatment-resistant fibromyalgia. The beneficial effects became clear within 4 to 6 weeks and persisted throughout the entire 14-month observation period.
Spironolactone Targets Retinoid X Receptor γ to Promote Myelin Sheath Regeneration
Published in Neurology: Neuroimmunology & Neuroinflammation, this study proves that spironolactone crosses into central nervous tissues to directly suppress microglial activation. The researchers discovered that the drug acts as an RXRγ agonist, uncovering a hidden pathway that promotes myelin repair—the central structural barrier damaged in Multiple Sclerosis (MS)
Spironolactone Use And Neurocognitive Outcomes Among Patients With Heart Failure And Reduced Ejection Fraction
An analysis of over 44,000 propensity-matched patient records from the TriNetX health network examined the 3-year incidence of neurocognitive diagnoses. The data revealed that patients prescribed the MR antagonist spironolactone experienced an 18% lower risk of developing Alzheimer's disease and a 9% lower risk of all-cause dementia
A second act for spironolactone: cognitive benefits in renal dysfunction - a critical review
A 2025 critical review in Metabolic Brain Disease confirms that spironolactone functions as a neuroprotective agent and cellular stabilizer by crossing the blood-brain barrier. The research demonstrates that the medication restores barrier integrity, regulates cerebral blood flow, and suppresses the NF-κB inflammatory pathway and NADPH-oxidase to halt localized tissue swelling.
The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature
This 2019 review establishes that the Mineralocorticoid Receptor (MR) functions as a ligand-activated transcription factor that directly modulates genes controlling tissue inflammation, oxidative stress, and progressive fibrosis across vascular and immune systems.
Clinical Evidence for MR Antagonists
This review pulls together decades of existing, peer-reviewed literature to map out the safety and profound effectiveness of mineralocorticoid receptor (MR) antagonists across a wide variety of conditions. By synthesizing global clinical data, this research demonstrates that targeted MR blockade is not a niche treatment, but a foundational, safe intervention capable of arresting the systemic inflammation and fluid dysregulation that underpins modern chronic disease.
It's Fluid! Not Fat. Rethinking Obesity
This groundbreaking framework challenges the conventional, multi-billion-dollar calorie narrative by redefining obesity at its root. Instead of treating weight management as a simple struggle against fat accumulation, this research posits that the core issue is often chronic, tissue-level fluid retention driven by upstream mineralocorticoid receptor overdrive and capillary leaks. By treating the underlying cellular inflammation rather than counting calories, this article exposes why mainstream treatments fail and offers a roadmap to successful weight management.
Logic Chain: If this is true, the system is blind
This document pieces together existing peer-reviewed data, including the Aldo-DHF data and the JUPITER trial, to demonstrate how a genetic "stuck switch" (rs5522) fuels a cellular "cortisol steal" that ignites vascular leaks and chronic inflammation.
Media
The Medium Series: Mapping rs5522 and Systemic Blindness
Written specifically for a lay audience, this collection of articles breaks down exactly how the rs5522 genetic variant causes disease and why mainstream medicine completely missed the underlying pattern.
